/ Not yet recruitingPhase 1 评估ZM001注射液治疗难治性的系统性红斑狼疮患者的安全性和有效性的I期临床研究
[Translation] A Phase I clinical study to evaluate the safety and efficacy of ZM001 injection in the treatment of refractory systemic lupus erythematosus patients
主要目的:评估ZM001治疗难治性系统性红斑狼疮患者的安全性并确定ZM001的Ⅱ期推荐剂量(RP2D)
次要目的:ZM001回输后对受试者临床疾病活动性的影响、受试者生活质量变化、抗药抗体情况及药代动力学和药效学特征
[Translation] Primary objective: To evaluate the safety of ZM001 in the treatment of patients with refractory systemic lupus erythematosus and determine the recommended Phase II dose (RP2D) of ZM001. Secondary objectives: The effect of ZM001 reinfusion on the clinical disease activity of the subjects, the changes in the subjects' quality of life, the status of anti-drug antibodies, and the pharmacokinetic and pharmacodynamic characteristics
100 Clinical Results associated with Xiamen Zaimiao Biotechnology Co., Ltd.
0 Patents (Medical) associated with Xiamen Zaimiao Biotechnology Co., Ltd.
100 Deals associated with Xiamen Zaimiao Biotechnology Co., Ltd.
100 Translational Medicine associated with Xiamen Zaimiao Biotechnology Co., Ltd.